Darglitazone is primarily used in the management of type 2 diabetes mellitus. It functions as an insulin sensitizer, improving the body's response to insulin, particularly in muscle and adipose tissue. This helps in lowering blood glucose levels effectively. It is often prescribed when other treatments, such as metformin or sulfonylureas, do not provide adequate control of blood sugar. Additionally, it may be used in combination with other antidiabetic agents to enhance glycemic control. Darglitazone also shows potential in reducing cardiovascular risks associated with diabetes, though its use requires careful monitoring due to possible side effects like weight gain and fluid retention.